D
David Planchard
Researcher at Institut Gustave Roussy
Publications - 430
Citations - 28831
David Planchard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 55, co-authored 352 publications receiving 19769 citations. Previous affiliations of David Planchard include Université Paris-Saclay & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma
Nader Abedallaa,Lise Tremblay,Charlotte Baey,Dominique Fabre,David Planchard,Jean Pierre Pignon,Joël Guigay,Cécile Le Péchoux,Jean-Charles Soria,Vincent Thomas de Montpréville,Benjamin Besse +10 more
TL;DR: Perioperative chemotherapy may be beneficial in patients with resected SCLC or LCNEC that had been surgically removed between 1979 and 2007 at a single institution.
Journal ArticleDOI
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
TL;DR: The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting.
Journal ArticleDOI
1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
Roberto Ferrara,Caroline Caramella,M. Texier,C. Audigier Valette,Laurent Tessonnier,Laura Mezquita,J. Lahmar,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Virginie Westeel,S. Le Moulec,L. Leroy,Boris Duchemann,Remi Veillon,David Planchard,M-E. Boucher,Serge Koscielny,J-C. Soria,Benjamin Besse +19 more
Journal ArticleDOI
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).
George R. Blumenschein,Egbert F. Smit,David Planchard,Dong Wan Kim,Jacques Cadranel,Tommaso De Pas,Frank Dunphy,Katalin Udud,Myung-Ju Ahn,Nasser H. Hanna,Joo Hang Kim,Julien Mazieres,Sang-We Kim,Paul Baas,E. Rappold,Suman Redhu,Kevin M. Bellew,Michael R. W. Streit,Frank S. Wu,Pasi A. Jänne +19 more
TL;DR: This phase II trial evaluated the efficacy of T vs D in pts with advanced KRAS-mutant NSCLC who had received prior platinum-based chemotherapy and was stopped early for futility.
Journal ArticleDOI
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.
S. Ortiz-Cuaran,Laura Mezquita,Aurélie Swalduz,Mihaela Aldea,Julien Mazieres,Camille Leonce,Cécile Jovelet,Anne Pradines,V. Avrillon,Washington René Chumbi Flores,Ludovic Lacroix,Yohann Loriot,Virginie Westeel,Maud Ngo-Camus,Claire Tissot,C. Raynaud,Radj Gervais,Etienne Brain,Isabelle Monnet,Etienne Giroux Leprieur,Caroline Caramella,Celine Mahier Ait Oukhatar,N. Hoog-Labouret,Frank de Kievit,Karen Howarth,Clive Morris,Emma Green,Luc Friboulet,Sylvie Chabaud,Jean-François Guichou,Maurice Perol,Benjamin Besse,Jean-Yves Blay,Pierre Saintigny,David Planchard +34 more
TL;DR: In this article, the authors evaluated the clinical utility of circulating tumor DNA (ctDNA)-targeted sequencing to identify canonical BRAF mutations and genomic alterations potentially related to resistance to BRAF-TT, in a large cohort of patients with BRAFmutant NSCLC.